AstraZeneca PLC
AZN rates a BUY because the stock is pricing LOE and China pressure more heavily than a still-intact path to mid to high single-digit FY26 revenue growth, low double-digit core EPS growth, and a deep late-stage pipeline that management still believes supports $80B revenue by 2030.
The market is discounting AZN like a company entering a harder post-LOE stretch, and that part is fair, but it is not fully crediting how much of the business is still growing underneath the Farxiga and Brilinta drag. H1 revenue grew 6%, yet management said underlying growth was 11% excluding Farxiga and Brilinta LOE impact. That matters because it shows the core franchise has not stalled. It is absorbing legacy erosion while still funding a large R&D budget and an elevated manufacturing buildout.
The stock also offers a better setup than the headline multiple suggests. At 25.06x P/E and 4.26x P/S, AZN trades below peer averages of 29.5x and 5.5x despite a cleaner growth profile than many large-cap pharma names facing steeper patent cliffs. Shares are already 20.8% below the 52-week high and 7.8% below the 200-day average after a 11.83% three-month drawdown, so the market has de-risked the name before any formal guide cut. If October confirms the reiterated FY26 framework, some of that discount should close.
The case depends on three things. First, management must prove that low double-digit core EPS growth is still achievable even with lower 2H gross margin, milestone payments of about $2.5B, and CapEx up roughly 33%. Second, launches need to bridge the gap left by LOE. Management highlighted Datroway, Etcamah, and Baxfendy as each having >$5B peak sales potential, and said Baxfendy access should widen over the next few quarters ahead of Medicare Part D reimbursement from 2028. Third, pipeline momentum has to stay real, not promotional. The 6 positive Phase III readouts in H1 help, but CARDIO-TTRansform's failure is a reminder that not all of the 2030 story will show up.
Conviction stays at Medium because the balance sheet and cash conversion do not justify a full-throated call. FCF of $2.1B is thin for a $261.1B company carrying $32.2B of debt, and the current ratio is only 0.89. Still, the stock does not need perfection. It needs the current guidance to hold, launch revenue to broaden, and the market to recognize that AZN remains a growth pharma company, not an ex-growth patent-loss story.
Pipeline wins convert faster, Baxfendy and other launches broaden access, and the market pays closer to peer multiples for a still-credible 2030 growth path.
AZN delivers reiterated FY26 guidance, launches offset most legacy erosion, and valuation moves toward the engine's earnings-growth blend target.
LOE in Farxiga and Brilinta deepens, China pricing stays weak, and reiterated guidance proves too ambitious as 2H gross margin falls.
No analyst coverage available to cross-check.
I don't want a lot of good investments; I want a few outstanding ones.
Forward earnings power still looks better than the trailing headline implies. Management is guiding low double-digit core EPS growth in FY26 against a stock on 25.06x trailing P/E, so the effective forward multiple should compress if the company simply delivers what it already reiterated. The moat looks stable now and still credible in 3-5 years because AZN is replacing mature products with oncology, rare disease, and next-wave launches, though durability depends on converting the recent 6 positive Phase III readouts into commercial products before LOE broadens. AI is more tailwind than disruption here, mainly by improving trial design, biomarker selection, and R&D productivity, but regulation and payer pressure, especially China VBP/NRDL and U.S. reimbursement scrutiny, will determine how much of the pipeline translates into price and margin.
- FY26 guidance was reiterated for mid to high single-digit revenue growth and low double-digit core EPS growth, supported by 6% H1 revenue growth and 11% H1 core EPS growth.
- Valuation sits below peers at 25.06x P/E versus 29.5x and 4.26x P/S versus 5.5x, while the stock trades 20.8% below the 52-week high.
- Pipeline and launch cadence remains active with 6 positive Phase III readouts in H1 and management citing Datroway, Etcamah, and Baxfendy as each having >$5B peak sales potential.
- Execution has been consistently solid: AZN beat or met EPS estimates in 8 straight quarters, including +5.2%, +12.7%, and +4.4% beats in the last six reported quarters.
- Underlying demand is better than the headline: H1 revenue rose 6%, but management said underlying growth was 11% excluding Farxiga and Brilinta LOE impact, showing the growth engine still works outside aging products.
- Profit structure is holding despite investment: FY2025 operating margin improved to 19.2% from 18.5%, and FY26 core gross margin is guided stable to slightly higher versus 2025 even with R&D at the upper end of low 20s % of revenue.
- The stock has already corrected: shares are down 11.83% over 3 months, 20.8% below the 52-week high, and below the $182.62 200-day average, which leaves room for recovery if October results confirm guidance.
- LOE is real and current: Biopharma was -5% in H1 as Farxiga, Brilinta, and roxadustat erosion offset part of respiratory growth, and management expects working-capital drag from U.S. Farxiga LOE through the rest of FY26.
- Guidance was only reiterated, not raised, despite strong H1 execution, which suggests less cushion in 2H and management caution around mix, China, and generic erosion.
- Cash generation looks weak relative to scale: FY2025 revenue was $58.7B, but FCF was only $2.1B, while total debt stands at $32.2B, debt/EBITDA is 1.62, and current ratio is 0.89.
- Not every pipeline bet is landing: CARDIO-TTRansform failed its primary endpoint, reminding investors that some of the 2030 bridge depends on uncertain clinical outcomes.
| Metric | Value | Context |
|---|---|---|
| Current price | $168.37 | Reference price for the $196.38 target |
| Price target | $196.38 | 16.6% upside, Medium confidence, basis earnings_growth_blend |
| FY2025 revenue | $58.7B | 11.9% YoY growth |
| FY2025 EPS | $6.60 | -13.5% YoY, showing earnings pressure despite revenue growth |
| Operating margin | 19.2% | Up from 18.5% in the prior FY |
| Net margin | 14.1% | Profitable, but not yet reflecting full pipeline operating leverage |
| Valuation | P/E 25.06x, P/S 4.26x | Below peer averages of 29.5x P/E and 5.5x P/S |
| Balance sheet | Debt/Equity 0.64, Debt/EBITDA 1.62 | Leverage is manageable, liquidity tighter with current ratio 0.89 |
| Free cash flow | $2.1B | Weak relative to $58.7B revenue and elevated investment needs |
| FY26 guidance | Revenue mid to high single-digit %, Core EPS low double-digit % | Reiterated on the 2026 Q2 call |
| Q2 FY26 EBITDA | $5.16B | 33.6% margin, down 350 bps vs Q1 and 70 bps YoY |
| 52-week position | -20.8% vs high, -7.8% vs 200-day average | Setup is less crowded after a -11.83% 3-month move |
The biggest risk is that LOE and pricing pressure outrun launches, especially with Biopharma already -5% in H1 and working-capital drag from U.S. Farxiga LOE expected through the rest of FY26.
FY26 Q3 earnings on October 30, 2026, where investors need confirmation that H1's 11% core EPS growth can absorb lower 2H gross margin and ongoing LOE pressure without a guide-down.
Ownership is concentrated but stable, with the top three institutions holding 42.9%, which usually dampens squeeze dynamics and favors longer-duration holders. Short interest is negligible at 0.19% of shares, or 2.9M shares with 1 day-to-cover, so the long case does not rely on a short-covering bid. Options positioning is supportive, with a positive GEX regime and zero-gamma at $142.84, about 14.67% below spot, implying the dealer setup is not currently amplifying downside unless the stock breaks much lower.
H1 was -5%, as Farxiga, Brilinta, and roxadustat LOE pressure only partly offset respiratory growth.
Management cited these areas as the main demand drivers behind 11% H1 core EPS growth and the late-stage pipeline remains active.
Growth remains pressured by VBP/NRDL dynamics, a recurring drag first flagged in 2024 and still unresolved in 2026.
Farxiga LOE is creating both revenue and working-capital pressure through the rest of FY26.
AZN reiterated FY26 guidance as pipeline wins and launches offset LOE pressure.
Management has earned a reasonable level of credibility. On the 2024 Q3 call, the company raised FY24 guidance to high teens revenue and core EPS growth and said it was managing the P&L toward a mid-30s percentage operating margin by 2026 while keeping confidence in $80B revenue by 2030. Since then, AZN has delivered 8 straight quarterly EPS beats or meets, including a +12.7% beat in April 2025 and +5.2% in July 2026, and FY2025 revenue grew 11.9% to $58.7B with operating margin improving to 19.2% from 18.5%. The miss versus the older aspiration is margin, because Q2 FY26 EBITDA margin was 33.6%, below Q1's 37.1% and only modestly below the 2024 Q3 level of 34.4%, while gross margin is expected to be lower in 2H due to mix. Strategy has not changed materially: management is still pressing the same playbook of investing through LOE, adding manufacturing, and leaning on pipeline depth, but the pace of margin delivery looks slower than the 2024 rhetoric implied.
We are reiterating our outlook for the full year. We expect total revenue to increase by a mid- to high single-digit percentage and core EPS to increase by low double-digit percentage at constant exchange rates.
While the margin improved in the second quarter compared to the first quarter, we expect lower gross margin in the second half, consistent with prior years, reflecting seasonal demand patterns for lower-margin medicines such as FluMist and Beyfortus.
I'm really pleased to report that in the first half of '26, we saw strong growth momentum and continued pipeline delivery.
The breadth and depth of our pipeline remain exceptional and our confidence in reaching $80 billion revenue by 2030 is intact.
We anticipate commercial access for Baxfendy will broaden over the next few quarters in anticipation of Medicare Part D reimbursement from 2028.
AZN's moat rests on a broad patent-protected portfolio, global commercial scale, and unusually deep innovation throughput, reflected in an Innovation Investment score of 98 and 6 positive Phase III readouts in H1. The moat is strongest in oncology and rare disease, where clinical differentiation and physician adoption can sustain premium pricing longer than in primary care. Durability is good, not perfect, because the company is actively replenishing LOE exposure, but pressure in China and U.S. generic erosion show the moat is narrower in mature products than in specialty launches.
Capital allocation is currently tilted toward reinvestment, not shareholder distribution. FY26 CapEx is set to rise about 33%, including ADC manufacturing in Singapore, and management has also spent >$2B in YTD business development upfronts, including a $1.2B upfront for CSPC in Q2. That is strategically sensible for a pipeline-led model, but with only $2.1B FCF, $32.2B of debt, and no buybacks in the data provided, the burden is on management to prove these investments convert into durable revenue rather than just a bigger cost base.
AZN rates BUY, Medium conviction. The stock offers a reasonable entry because the valuation is below peers, the shares have already corrected, and the company is still guiding real earnings growth through a live LOE cycle. The case is not about flawless execution. It is about whether launches and pipeline depth can keep growth above the drag from Farxiga, Brilinta, China pricing, and seasonal margin pressure. A downgrade to HOLD would require either a break in the serial beat pattern on October 30 or evidence that FY26 guidance no longer holds.
≣ Full research note tap to expand
Executive Summary
BUY, Medium conviction. Rated BUY, Medium conviction. At $168.37, AZN sits 20.8% below its 52-week high and 7.8% below its 200-day average even as management reiterated FY26 for mid to high single-digit revenue growth and low double-digit core EPS growth after 11% H1 core EPS growth. The stock is not cheap in absolute terms at 25.06x P/E, but it is below the 29.5x peer average, and the setup is helped by a serial beat record, broad pipeline progress, and a base-case target of $196.38.
Investment Thesis
The market is discounting AZN like a company entering a harder post-LOE stretch, and that part is fair, but it is not fully crediting how much of the business is still growing underneath the Farxiga and Brilinta drag. H1 revenue grew 6%, yet management said underlying growth was 11% excluding Farxiga and Brilinta LOE impact. That matters because it shows the core franchise has not stalled. It is absorbing legacy erosion while still funding a large R&D budget and an elevated manufacturing buildout.
The stock also offers a better setup than the headline multiple suggests. At 25.06x P/E and 4.26x P/S, AZN trades below peer averages of 29.5x and 5.5x despite a cleaner growth profile than many large-cap pharma names facing steeper patent cliffs. Shares are already 20.8% below the 52-week high and 7.8% below the 200-day average after a 11.83% three-month drawdown, so the market has de-risked the name before any formal guide cut. If October confirms the reiterated FY26 framework, some of that discount should close.
The case depends on three things. First, management must prove that low double-digit core EPS growth is still achievable even with lower 2H gross margin, milestone payments of about $2.5B, and CapEx up roughly 33%. Second, launches need to bridge the gap left by LOE. Management highlighted Datroway, Etcamah, and Baxfendy as each having >$5B peak sales potential, and said Baxfendy access should widen over the next few quarters ahead of Medicare Part D reimbursement from 2028. Third, pipeline momentum has to stay real, not promotional. The 6 positive Phase III readouts in H1 help, but CARDIO-TTRansform's failure is a reminder that not all of the 2030 story will show up.
Conviction stays at Medium because the balance sheet and cash conversion do not justify a full-throated call. FCF of $2.1B is thin for a $261.1B company carrying $32.2B of debt, and the current ratio is only 0.89. Still, the stock does not need perfection. It needs the current guidance to hold, launch revenue to broaden, and the market to recognize that AZN remains a growth pharma company, not an ex-growth patent-loss story.
Key Metrics
| Metric | Value | Context |
|---|---|---|
| Current price | $168.37 | Reference price for the $196.38 target |
| Price target | $196.38 | 16.6% upside, Medium confidence, basis earnings_growth_blend |
| FY2025 revenue | $58.7B | 11.9% YoY growth |
| FY2025 EPS | $6.60 | -13.5% YoY, showing earnings pressure despite revenue growth |
| Operating margin | 19.2% | Up from 18.5% in the prior FY |
| Net margin | 14.1% | Profitable, but not yet reflecting full pipeline operating leverage |
| Valuation | P/E 25.06x, P/S 4.26x | Below peer averages of 29.5x P/E and 5.5x P/S |
| Balance sheet | Debt/Equity 0.64, Debt/EBITDA 1.62 | Leverage is manageable, liquidity tighter with current ratio 0.89 |
| Free cash flow | $2.1B | Weak relative to $58.7B revenue and elevated investment needs |
| FY26 guidance | Revenue mid to high single-digit %, Core EPS low double-digit % | Reiterated on the 2026 Q2 call |
| Q2 FY26 EBITDA | $5.16B | 33.6% margin, down 350 bps vs Q1 and 70 bps YoY |
| 52-week position | -20.8% vs high, -7.8% vs 200-day average | Setup is less crowded after a -11.83% 3-month move |
Financial Strength
AZN's balance sheet is adequate, not pristine. Leverage at 1.62x debt/EBITDA is manageable for a large pharma business with durable gross profits, and debt/equity of 0.64 is not alarming. The issue is cash conversion: $2.1B FCF is light relative to $58.7B of revenue, especially with CapEx set to rise 33%, milestone payments around $2.5B, and working-capital drag from U.S. Farxiga LOE still ahead. Margin direction is mixed, with FY2025 operating margin improving to 19.2%, but Q2 EBITDA margin slipping to 33.6% and 2H gross margin guided lower on mix.
Competitive Position
AZN's moat rests on a broad patent-protected portfolio, global commercial scale, and unusually deep innovation throughput, reflected in an Innovation Investment score of 98 and 6 positive Phase III readouts in H1. The moat is strongest in oncology and rare disease, where clinical differentiation and physician adoption can sustain premium pricing longer than in primary care. Durability is good, not perfect, because the company is actively replenishing LOE exposure, but pressure in China and U.S. generic erosion show the moat is narrower in mature products than in specialty launches.
Management & Guidance
Current guidance is credible but not conservative enough to dismiss risk. Management reiterated that, "We are reiterating our outlook for the full year. We expect total revenue to increase by a mid- to high single-digit percentage and core EPS to increase by low double-digit percentage at constant exchange rates." That is supported by 6% H1 revenue growth and 11% H1 core EPS growth, plus a multi-quarter beat record. The caution flags are explicit: CFO also said, "While the margin improved in the second quarter compared to the first quarter, we expect lower gross margin in the second half, consistent with prior years, reflecting seasonal demand patterns for lower-margin medicines such as FluMist and Beyfortus." Given reiterated, not raised, guidance after a decent H1, management is signaling confidence, but not surplus cushion.
Segment Analysis
- Biopharma (N/A): H1 was -5%, as Farxiga, Brilinta, and roxadustat LOE pressure only partly offset respiratory growth.
- Oncology and Rare Disease (N/A): Management cited these areas as the main demand drivers behind 11% H1 core EPS growth and the late-stage pipeline remains active.
- China (N/A): Growth remains pressured by VBP/NRDL dynamics, a recurring drag first flagged in 2024 and still unresolved in 2026.
- U.S. (N/A): Farxiga LOE is creating both revenue and working-capital pressure through the rest of FY26.
Capital Allocation
Capital allocation is currently tilted toward reinvestment, not shareholder distribution. FY26 CapEx is set to rise about 33%, including ADC manufacturing in Singapore, and management has also spent >$2B in YTD business development upfronts, including a $1.2B upfront for CSPC in Q2. That is strategically sensible for a pipeline-led model, but with only $2.1B FCF, $32.2B of debt, and no buybacks in the data provided, the burden is on management to prove these investments convert into durable revenue rather than just a bigger cost base.
Management Execution & Track Record
Management has earned a reasonable level of credibility. On the 2024 Q3 call, the company raised FY24 guidance to high teens revenue and core EPS growth and said it was managing the P&L toward a mid-30s percentage operating margin by 2026 while keeping confidence in $80B revenue by 2030. Since then, AZN has delivered 8 straight quarterly EPS beats or meets, including a +12.7% beat in April 2025 and +5.2% in July 2026, and FY2025 revenue grew 11.9% to $58.7B with operating margin improving to 19.2% from 18.5%. The miss versus the older aspiration is margin, because Q2 FY26 EBITDA margin was 33.6%, below Q1's 37.1% and only modestly below the 2024 Q3 level of 34.4%, while gross margin is expected to be lower in 2H due to mix. Strategy has not changed materially: management is still pressing the same playbook of investing through LOE, adding manufacturing, and leaning on pipeline depth, but the pace of margin delivery looks slower than the 2024 rhetoric implied.
Positioning & Flows
Ownership is concentrated but stable, with the top three institutions holding 42.9%, which usually dampens squeeze dynamics and favors longer-duration holders. Short interest is negligible at 0.19% of shares, or 2.9M shares with 1 day-to-cover, so the long case does not rely on a short-covering bid. Options positioning is supportive, with a positive GEX regime and zero-gamma at $142.84, about 14.67% below spot, implying the dealer setup is not currently amplifying downside unless the stock breaks much lower.
Bull Case
- Execution has been consistently solid: AZN beat or met EPS estimates in 8 straight quarters, including +5.2%, +12.7%, and +4.4% beats in the last six reported quarters.
- Underlying demand is better than the headline: H1 revenue rose 6%, but management said underlying growth was 11% excluding Farxiga and Brilinta LOE impact, showing the growth engine still works outside aging products.
- Profit structure is holding despite investment: FY2025 operating margin improved to 19.2% from 18.5%, and FY26 core gross margin is guided stable to slightly higher versus 2025 even with R&D at the upper end of low 20s % of revenue.
- The stock has already corrected: shares are down 11.83% over 3 months, 20.8% below the 52-week high, and below the $182.62 200-day average, which leaves room for recovery if October results confirm guidance.
Bear Case
- LOE is real and current: Biopharma was -5% in H1 as Farxiga, Brilinta, and roxadustat erosion offset part of respiratory growth, and management expects working-capital drag from U.S. Farxiga LOE through the rest of FY26.
- Guidance was only reiterated, not raised, despite strong H1 execution, which suggests less cushion in 2H and management caution around mix, China, and generic erosion.
- Cash generation looks weak relative to scale: FY2025 revenue was $58.7B, but FCF was only $2.1B, while total debt stands at $32.2B, debt/EBITDA is 1.62, and current ratio is 0.89.
- Not every pipeline bet is landing: CARDIO-TTRansform failed its primary endpoint, reminding investors that some of the 2030 bridge depends on uncertain clinical outcomes.
Valuation & Price Target
Engine price target $196.38 (+16.6% vs current), Medium confidence.
- P/E Multiple: $222.03 (28% weight)
- PEG (growth-adjusted): $119.95 (20% weight)
- P/S Multiple: $208.31 (20% weight)
- Quality-adjusted: $187.23 (20% weight)
- DCF: $477.98 (3% weight)
The rating aligns with the quant baseline BUY (Medium conviction), but for a narrower reason set than the DCF might suggest. The engine's blended target is $196.38, with the spread across methods showing real uncertainty: P/E $222.03, P/S $208.31, Quality-adjusted $187.23, PEG $119.95, and an outlier DCF $477.98. The right anchor is the middle of that range, not the DCF, because peer dispersion is wide at 5.4x P/E, LOE is active, and FCF is only $2.1B. No sell-side coverage is available to cross-check, which matters little here because the decision rests on company data: a below-peer multiple, reiterated FY26 growth, and a stock already 20.8% below its high.
Risk Assessment
Risk score 43/100 (Moderate). The biggest risk is that LOE and pricing pressure outrun launches, especially with Biopharma already -5% in H1 and working-capital drag from U.S. Farxiga LOE expected through the rest of FY26.
The Bottom Line
AZN rates BUY, Medium conviction. The stock offers a reasonable entry because the valuation is below peers, the shares have already corrected, and the company is still guiding real earnings growth through a live LOE cycle. The case is not about flawless execution. It is about whether launches and pipeline depth can keep growth above the drag from Farxiga, Brilinta, China pricing, and seasonal margin pressure. A downgrade to HOLD would require either a break in the serial beat pattern on October 30 or evidence that FY26 guidance no longer holds.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr